Maze Therapeutics Inc [MAZE] stock prices are up 8.76% to $44.34 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The MAZE shares have gain 10.33% over the last week, with a monthly amount glided 15.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maze Therapeutics Inc [NASDAQ: MAZE] stock has seen the most recent analyst activity on December 04, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $55. On September 02, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $30 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $34 on July 23, 2025. Wedbush initiated its recommendation with a Outperform and recommended $17 as its price target on July 08, 2025.
The stock price of Maze Therapeutics Inc [MAZE] has been fluctuating between $6.71 and $43.29 over the past year. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $44.34 at the most recent close of the market. An investor can expect a potential return of 15.02% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
The Maze Therapeutics Inc [NASDAQ:MAZE] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.45 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Maze Therapeutics Inc [NASDAQ:MAZE]’s Current Ratio is 17.70. On the other hand, the Quick Ratio is 17.70, and the Cash Ratio is 14.33.
Transactions by insiders
Recent insider trading involved SEKAR KATHIRESAN, Former Director, that happened on Jan 16 ’26 when 29772.0 shares were purchased. President, R&D & CMO, Bernstein Harold completed a deal on Jan 07 ’26 to sell 25156.0 shares. Meanwhile, Director Sohn Catherine A. sold 26920.0 shares on Jan 07 ’26.
